MICHAEL TAYLOR to beta Catenin
This is a "connection" page, showing publications MICHAEL TAYLOR has written about beta Catenin.
Connection Strength
0.498
-
Medulloblastoma in the age of molecular subgroups: a review. J Neurosurg Pediatr. 2019 10 01; 24(4):353-363.
Score: 0.142
-
TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol. 2010 Dec 10; 28(35):5188-96.
Score: 0.076
-
Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011 Apr 10; 29(11):1408-14.
Score: 0.076
-
Failure of a medulloblastoma-derived mutant of SUFU to suppress WNT signaling. Oncogene. 2004 Jun 03; 23(26):4577-83.
Score: 0.049
-
WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathol Commun. 2014 Dec 24; 2:174.
Score: 0.025
-
Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathol. 2014 Jul; 128(1):137-49.
Score: 0.024
-
Medulloblastomics: the end of the beginning. Nat Rev Cancer. 2012 Dec; 12(12):818-34.
Score: 0.022
-
Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012 Aug 02; 488(7409):106-10.
Score: 0.022
-
Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012 Aug 02; 488(7409):100-5.
Score: 0.022
-
Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathol. 2012 Apr; 123(4):515-27.
Score: 0.021
-
Rapid diagnosis of medulloblastoma molecular subgroups. Clin Cancer Res. 2011 Apr 01; 17(7):1883-94.
Score: 0.019